Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

This publication has 23 references indexed in Scilit:

• Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100
  Drug Metabolism and Disposition, 2007
• Model-based drug development applied to oncology
  Expert Opinion on Drug Discovery, 2007
• Comparison of Pharmacodynamic and Pharmacokinetic Indices of Efficacy for 5 Fluoroquinolones toward Pathogens of Dogs and Cats
  Journal of Veterinary Internal Medicine, 2006
• Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B
  Circulation, 2006
• An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
  Journal of Lipid Research, 2005
• PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-α PHOSPHOROTHIOATE 2′-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES
  Drug Metabolism and Disposition, 2003
• Apolipoprotein B: mRNA Editing, Lipoprotein Assembly, and Presecretory Degradation
  Annual Review of Nutrition, 2000
• Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers
  The Journal of Clinical Pharmacology, 2000
• Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression
  Journal of Biological Chemistry, 1999
• Identification and Partial Purification of Human Double Strand RNase Activity
  Journal of Biological Chemistry, 1998